Tekmira Pharmaceuticals Corp (TKMR) (TKMR)

[Echo20]

Historical PR:

Tiny Tekmira Lands $65M Settlement Plus $10M in Near-Term Milestone Payments from Alnylam

On the eve of their transformational legal trial, emerging developer Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO) announced after the market close on Monday that they had settled all litigation matters between the firm and Alnylam Pharmaceuticals, Inc. (ALNY) - whose shares dropped -4.23% After Hours to $15.44 on the news.

Tekmira, which closed Monday`s session with a $70M market cap will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.

For the speculators who were betting on a positive outcome for the pending trial, the impact should be understandibly positive.

Tekmira is now funded with over $4.00 per share in cash alone thanks to their friends at Alnylam. Perhaps more importantly, observers who know the sector argue that the key settlement now positions Tekmira as the undisputed leading delivery owner of RNA interference (RNAi) therapeutics and enables them to soon to have the largest RNAi drug opportunity.
__________________________________________________________________


Before the case TKMR was at $7.00 per share. (after a reverse stock split.)

The case knocked down the price of TKMR to $3.50.

With the case over the price of TKMR could go up 100% by that alone.

TKMR now the undisputed owner of IRNA delivery could be sought after by many PHARMACEUTICAL COMPANIES.

Echo20